These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 19757871)

  • 1. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
    White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
    Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
    Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
    Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs associated with herpes zoster in the US.
    Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
    J Med Econ; 2016 Oct; 19(10):928-35. PubMed ID: 27149530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.
    Insinga RP; Itzler RF; Pellissier JM
    Pharmacoeconomics; 2007; 25(2):155-69. PubMed ID: 17249857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.
    Gialloreti LE; Merito M; Pezzotti P; Naldi L; Gatti A; Beillat M; Serradell L; di Marzo R; Volpi A
    BMC Infect Dis; 2010 Aug; 10():230. PubMed ID: 20682044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care utilization and cost burden of herpes zoster in a community population.
    Yawn BP; Itzler RF; Wollan PC; Pellissier JM; Sy LS; Saddier P
    Mayo Clin Proc; 2009 Sep; 84(9):787-94. PubMed ID: 19720776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
    Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
    BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
    Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
    Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
    Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
    Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
    Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G
    BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
    Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
    J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
    Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
    Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
    [No Abstract]   [Full Text] [Related]  

  • 14. Costs of herpes zoster complications in older adults: A cohort study of US claims database.
    Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
    Vaccine; 2019 Feb; 37(9):1235-1244. PubMed ID: 30685248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK.
    Matthews I; Duong M; Parsons VL; Nozad B; Qizilbash N; Patel Y; Guimicheva B
    PLoS One; 2020; 15(2):e0229224. PubMed ID: 32097441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M; Marra CA; Galanis E; Patrick DM
    Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.
    Gauthier A; Breuer J; Carrington D; Martin M; Rémy V
    Epidemiol Infect; 2009 Jan; 137(1):38-47. PubMed ID: 18466661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
    Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B; Köster I; Reinhold T; Siedler A; Krause G; Icks A; Schubert I; Wichmann O
    Eur J Health Econ; 2013 Dec; 14(6):1015-26. PubMed ID: 23271349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia.
    Gudin J; Fudin J; Wang E; Haylon T; Patel K; Goss TF
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1387-1396. PubMed ID: 31589557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.